ES2346572T3 - Inmunoensayo turbidimetrico para evaluar cistatina c humana. - Google Patents

Inmunoensayo turbidimetrico para evaluar cistatina c humana.

Info

Publication number: ES2346572T3
Authority: ES; Spain
Prior art keywords: cystatin; mixture; antibodies; concentration; per
Prior art date: 2005-11-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES06849520T

Other languages

English (en)

Spanish (es)

Inventor

Kathrin Sunde

Tom Nilsen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Gentian AS

Original Assignee

Gentian AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-24

Filing date

2006-11-24

Publication date

2010-10-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37708396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2346572(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-11-24 Priority claimed from NO20055561A external-priority patent/NO20055561D0/no

2005-11-28 Priority claimed from NO20055603A external-priority patent/NO20055603D0/no

2006-11-24 Application filed by Gentian AS filed Critical Gentian AS

2010-10-18 Application granted granted Critical

2010-10-18 Publication of ES2346572T3 publication Critical patent/ES2346572T3/es

Status Active legal-status Critical Current

2026-11-24 Anticipated expiration legal-status Critical

Links

238000012360 testing method Methods 0.000 title claims abstract description 170
102000012192 Cystatin C Human genes 0.000 claims abstract description 285
108010061642 Cystatin C Proteins 0.000 claims abstract description 285
239000000203 mixture Substances 0.000 claims abstract description 191
238000003018 immunoassay Methods 0.000 claims abstract description 79
239000002105 nanoparticle Substances 0.000 claims abstract description 59
238000005259 measurement Methods 0.000 claims abstract description 47
101000912205 Homo sapiens Cystatin-C Proteins 0.000 claims abstract description 40
102000049632 human CST3 Human genes 0.000 claims abstract description 40
230000008859 change Effects 0.000 claims abstract description 38
239000000427 antigen Substances 0.000 claims abstract description 27
102000036639 antigens Human genes 0.000 claims abstract description 27
108091007433 antigens Proteins 0.000 claims abstract description 27
239000011248 coating agent Substances 0.000 claims abstract description 19
238000000576 coating method Methods 0.000 claims abstract description 19
239000000463 material Substances 0.000 claims abstract description 18
239000012634 fragment Substances 0.000 claims abstract description 12
239000007788 liquid Substances 0.000 claims abstract description 12
238000000034 method Methods 0.000 claims description 176
239000002245 particle Substances 0.000 claims description 102
102000004169 proteins and genes Human genes 0.000 claims description 47
108090000623 proteins and genes Proteins 0.000 claims description 47
239000003153 chemical reaction reagent Substances 0.000 claims description 40
238000002835 absorbance Methods 0.000 claims description 39
239000000872 buffer Substances 0.000 claims description 34
238000002156 mixing Methods 0.000 claims description 25
102000015833 Cystatin Human genes 0.000 claims description 19
108050004038 cystatin Proteins 0.000 claims description 19
238000011156 evaluation Methods 0.000 claims description 17
241000271566 Aves Species 0.000 claims description 15
150000003626 triacylglycerols Chemical class 0.000 claims description 15
239000012131 assay buffer Substances 0.000 claims description 13
230000024924 glomerular filtration Effects 0.000 claims description 13
238000001261 affinity purification Methods 0.000 claims description 12
108010088751 Albumins Proteins 0.000 claims description 11
102000009027 Albumins Human genes 0.000 claims description 11
241000894007 species Species 0.000 claims description 9
241000124008 Mammalia Species 0.000 claims description 7
241000238586 Cirripedia Species 0.000 claims description 3
102000014702 Haptoglobin Human genes 0.000 claims description 3
108050005077 Haptoglobin Proteins 0.000 claims description 3
241000283984 Rodentia Species 0.000 claims description 3
238000002405 diagnostic procedure Methods 0.000 claims description 3
238000013213 extrapolation Methods 0.000 claims description 3
108060003552 hemocyanin Proteins 0.000 claims description 3
230000008085 renal dysfunction Effects 0.000 claims description 3
229940127121 immunoconjugate Drugs 0.000 abstract description 11
239000000523 sample Substances 0.000 description 94
210000002966 serum Anatomy 0.000 description 88
235000018102 proteins Nutrition 0.000 description 45
238000010790 dilution Methods 0.000 description 30
239000012895 dilution Substances 0.000 description 30
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
239000012491 analyte Substances 0.000 description 20
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 20
229920000126 latex Polymers 0.000 description 20
239000004816 latex Substances 0.000 description 20
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 18
235000002639 sodium chloride Nutrition 0.000 description 17
238000004458 analytical method Methods 0.000 description 16
230000027455 binding Effects 0.000 description 16
239000000126 substance Substances 0.000 description 15
239000000725 suspension Substances 0.000 description 15
210000004027 cell Anatomy 0.000 description 13
238000010168 coupling process Methods 0.000 description 13
239000011780 sodium chloride Substances 0.000 description 13
230000008878 coupling Effects 0.000 description 12
238000005859 coupling reaction Methods 0.000 description 12
238000002360 preparation method Methods 0.000 description 12
239000000243 solution Substances 0.000 description 12
108010001160 IgY Proteins 0.000 description 11
238000002474 experimental method Methods 0.000 description 11
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 10
238000000692 Student's t-test Methods 0.000 description 10
229940109239 creatinine Drugs 0.000 description 10
239000000047 product Substances 0.000 description 10
239000004471 Glycine Substances 0.000 description 9
210000001124 body fluid Anatomy 0.000 description 9
239000010839 body fluid Substances 0.000 description 9
238000004364 calculation method Methods 0.000 description 9
238000000149 argon plasma sintering Methods 0.000 description 8
238000003556 assay Methods 0.000 description 8
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
150000002632 lipids Chemical class 0.000 description 8
239000002953 phosphate buffered saline Substances 0.000 description 8
238000000746 purification Methods 0.000 description 8
230000009257 reactivity Effects 0.000 description 8
239000007787 solid Substances 0.000 description 8
241000283973 Oryctolagus cuniculus Species 0.000 description 7
229920001213 Polysorbate 20 Polymers 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 7
230000021615 conjugation Effects 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
238000011835 investigation Methods 0.000 description 7
210000003205 muscle Anatomy 0.000 description 7
229920001223 polyethylene glycol Polymers 0.000 description 7
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 7
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 7
230000008569 process Effects 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
238000010998 test method Methods 0.000 description 7
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 6
239000002202 Polyethylene glycol Substances 0.000 description 6
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 6
230000008901 benefit Effects 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
235000013601 eggs Nutrition 0.000 description 6
238000005516 engineering process Methods 0.000 description 6
238000001914 filtration Methods 0.000 description 6
210000004408 hybridoma Anatomy 0.000 description 6
239000003550 marker Substances 0.000 description 6
229920000642 polymer Polymers 0.000 description 6
238000000611 regression analysis Methods 0.000 description 6
239000007790 solid phase Substances 0.000 description 6
238000012546 transfer Methods 0.000 description 6
238000005406 washing Methods 0.000 description 6
102000002322 Egg Proteins Human genes 0.000 description 5
108010000912 Egg Proteins Proteins 0.000 description 5
102000004338 Transferrin Human genes 0.000 description 5
108090000901 Transferrin Proteins 0.000 description 5
239000007983 Tris buffer Substances 0.000 description 5
230000005540 biological transmission Effects 0.000 description 5
238000011088 calibration curve Methods 0.000 description 5
239000000470 constituent Substances 0.000 description 5
239000011162 core material Substances 0.000 description 5
239000003599 detergent Substances 0.000 description 5
230000000694 effects Effects 0.000 description 5
235000013345 egg yolk Nutrition 0.000 description 5
210000002969 egg yolk Anatomy 0.000 description 5
230000001434 glomerular Effects 0.000 description 5
230000002452 interceptive effect Effects 0.000 description 5
238000012417 linear regression Methods 0.000 description 5
-1 polyethylene Polymers 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
229920005989 resin Polymers 0.000 description 5
239000011347 resin Substances 0.000 description 5
UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
239000012581 transferrin Substances 0.000 description 5
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
108060003951 Immunoglobulin Proteins 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
239000006180 TBST buffer Substances 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
229920001577 copolymer Polymers 0.000 description 4
238000001514 detection method Methods 0.000 description 4
238000002649 immunization Methods 0.000 description 4
230000003053 immunization Effects 0.000 description 4
102000018358 immunoglobulin Human genes 0.000 description 4
210000003734 kidney Anatomy 0.000 description 4
230000003907 kidney function Effects 0.000 description 4
239000004005 microsphere Substances 0.000 description 4
238000012545 processing Methods 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000013049 sediment Substances 0.000 description 4
238000000926 separation method Methods 0.000 description 4
239000002356 single layer Substances 0.000 description 4
238000004879 turbidimetry Methods 0.000 description 4
210000002700 urine Anatomy 0.000 description 4
102100032752 C-reactive protein Human genes 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
239000007987 MES buffer Substances 0.000 description 3
239000007993 MOPS buffer Substances 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000009833 condensation Methods 0.000 description 3
230000005494 condensation Effects 0.000 description 3
238000010276 construction Methods 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
230000037213 diet Effects 0.000 description 3
238000010494 dissociation reaction Methods 0.000 description 3
230000005593 dissociations Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000012149 elution buffer Substances 0.000 description 3
208000017169 kidney disease Diseases 0.000 description 3
239000010410 layer Substances 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
125000006850 spacer group Chemical group 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
101000766308 Bos taurus Serotransferrin Proteins 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
241001494479 Pecora Species 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
229920001328 Polyvinylidene chloride Polymers 0.000 description 2
208000001647 Renal Insufficiency Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
239000012148 binding buffer Substances 0.000 description 2
239000012928 buffer substance Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
235000013330 chicken meat Nutrition 0.000 description 2
239000007979 citrate buffer Substances 0.000 description 2
230000007012 clinical effect Effects 0.000 description 2
238000007405 data analysis Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
239000012470 diluted sample Substances 0.000 description 2
238000007865 diluting Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000010828 elution Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
229910052737 gold Inorganic materials 0.000 description 2
239000010931 gold Substances 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
201000006370 kidney failure Diseases 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
238000004848 nephelometry Methods 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
239000004800 polyvinyl chloride Substances 0.000 description 2
229920000915 polyvinyl chloride Polymers 0.000 description 2
239000005033 polyvinylidene chloride Substances 0.000 description 2
244000144977 poultry Species 0.000 description 2
235000013594 poultry meat Nutrition 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
201000001474 proteinuria Diseases 0.000 description 2
230000004044 response Effects 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
238000012353 t test Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
239000003656 tris buffered saline Substances 0.000 description 2
238000007817 turbidimetric assay Methods 0.000 description 2
IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
JQXYBDVZAUEPDL-UHFFFAOYSA-N 2-methylidene-5-phenylpent-4-enoic acid Chemical compound OC(=O)C(=C)CC=CC1=CC=CC=C1 JQXYBDVZAUEPDL-UHFFFAOYSA-N 0.000 description 1
DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
IWTYTFSSTWXZFU-UHFFFAOYSA-N 3-chloroprop-1-enylbenzene Chemical compound ClCC=CC1=CC=CC=C1 IWTYTFSSTWXZFU-UHFFFAOYSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
101710150365 Albumin-1 Proteins 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
108010032595 Antibody Binding Sites Proteins 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
206010003830 Automatism Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
108010074051 C-Reactive Protein Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000005927 Cysteine Proteases Human genes 0.000 description 1
108010005843 Cysteine Proteases Proteins 0.000 description 1
101100421536 Danio rerio sim1a gene Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
241000287826 Gallus Species 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 description 1
101000592517 Homo sapiens Puromycin-sensitive aminopeptidase Proteins 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
239000007990 PIPES buffer Substances 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108010073443 Ribi adjuvant Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
229910001508 alkali metal halide Inorganic materials 0.000 description 1
150000008045 alkali metal halides Chemical class 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
238000004164 analytical calibration Methods 0.000 description 1
230000009830 antibody antigen interaction Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000003139 biocide Substances 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000008827 biological function Effects 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000013626 chemical specie Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
150000001841 cholesterols Chemical class 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229910052681 coesite Inorganic materials 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000007334 copolymerization reaction Methods 0.000 description 1
229910052906 cristobalite Inorganic materials 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
230000006735 deficit Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
208000002296 eclampsia Diseases 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000003822 epoxy resin Substances 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000013100 final test Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000004927 fusion Effects 0.000 description 1
229910052732 germanium Inorganic materials 0.000 description 1
GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
235000008085 high protein diet Nutrition 0.000 description 1
230000005660 hydrophilic surface Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000005304 joining Methods 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000010197 meta-analysis Methods 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
239000000693 micelle Substances 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000003387 muscular Effects 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
210000002976 pectoralis muscle Anatomy 0.000 description 1
210000004976 peripheral blood cell Anatomy 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
239000012071 phase Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
229920000647 polyepoxide Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
210000000512 proximal kidney tubule Anatomy 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000013878 renal filtration Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000013214 routine measurement Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000010187 selection method Methods 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
239000011669 selenium Substances 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Chemical class [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 1
229910052814 silicon oxide Inorganic materials 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
229910052682 stishovite Inorganic materials 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000012536 storage buffer Substances 0.000 description 1
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
229920002994 synthetic fiber Polymers 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
239000010936 titanium Substances 0.000 description 1
OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
229910052905 tridymite Inorganic materials 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Analytical Chemistry (AREA)
Cell Biology (AREA)
Nanotechnology (AREA)
Food Science & Technology (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Peptides Or Proteins (AREA)
Investigating Or Analysing Materials By Optical Means (AREA)

ES06849520T 2005-11-24 2006-11-24 Inmunoensayo turbidimetrico para evaluar cistatina c humana. Active ES2346572T3 (es)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
NO20055561		2005-11-24
NO20055561A NO20055561D0 (no)	2005-11-24	2005-11-24	Turbidimetric Cystatin C immunoassay
NO20055603		2005-11-28
NO20055603A NO20055603D0 (no)	2005-11-28	2005-11-28	Cystatin C immunoassay
NO20062288		2006-05-19
NO20062288		2006-05-19

Publications (1)

Publication Number	Publication Date
ES2346572T3 true ES2346572T3 (es)	2010-10-18

Family

ID=37708396

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES06849520T Active ES2346572T3 (es)	2005-11-24	2006-11-24	Inmunoensayo turbidimetrico para evaluar cistatina c humana.

Country Status (11)

Country	Link
US (1)	US8263416B2 (fr)
EP (1)	EP1952154B1 (fr)
JP (2)	JP5147709B2 (fr)
AT (1)	ATE469351T1 (fr)
CA (1)	CA2627662C (fr)
DE (1)	DE602006014581D1 (fr)
DK (1)	DK1952154T3 (fr)
ES (1)	ES2346572T3 (fr)
PL (1)	PL1952154T3 (fr)
PT (1)	PT1952154E (fr)
WO (1)	WO2007102054A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2094832B1 (fr) *	2006-11-15	2015-04-22	The J. David Gladstone Institutes	Méthodes de réduction du niveau de l'amyloïde bêta
CN101680890B (zh)	2007-05-21	2014-05-07	根田股份有限公司	用于评估人抑半胱氨酸蛋白酶蛋白c的比浊免疫测定
CA2745610C (fr) *	2008-12-04	2017-10-31	Sekisui Medical Co., Ltd.	Procede pour mesurer la cystatine c dans un fluide corporel humain
CN102749458A (zh) *	2012-07-27	2012-10-24	北京恩济和生物科技有限公司	一种胱抑素c检测试剂盒及其制备方法
US20140162294A1 (en) *	2012-12-06	2014-06-12	General Atomics	Methods and compositions for assaying vitamin d
CN103217525B (zh) *	2013-03-21	2015-04-29	上海执诚生物科技股份有限公司	一种含有提高胱抑素c胶乳包被抗体的稳定性的组合物、稳定剂及其制备方法和用途
CN103645323B (zh) *	2013-08-02	2015-08-05	浙江夸克生物科技有限公司	一种胱抑素c检测试剂盒及其制备方法
CN104007259A (zh) *	2014-05-08	2014-08-27	北京玖佳宜科技有限公司	胱抑素c检测试剂盒及其制备
CN108489936B (zh) *	2018-04-08	2024-03-19	吉林省富生医疗器械有限公司	一种家用型胱抑素c浓度快速测定仪及其测定方法
CN109580936B (zh) *	2018-12-04	2022-03-04	蓝怡科技集团股份有限公司	一种微球试剂及其制备方法和应用
CN109813908A (zh) *	2018-12-29	2019-05-28	宁波普瑞柏生物技术股份有限公司	消除胱抑素c检测中钩状效应的方法和试剂盒
CN115161312B (zh) *	2021-04-06	2025-11-14	欧陆食品检测服务(大连)有限公司	一种食用油脂dna提取方法
JP2022161885A (ja) *	2021-04-08	2022-10-21	デンカ株式会社	免疫分析方法及び試薬

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4210723A (en) *	1976-07-23	1980-07-01	The Dow Chemical Company	Method of coupling a protein to an epoxylated latex
US4351824A (en) *	1981-02-05	1982-09-28	Icl Scientific	Polystyrene latex reagents, methods of preparation, and use in immunological procedures
DE4211351A1 (de) *	1992-04-04	1993-10-07	Behringwerke Ag	Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung
US6200820B1 (en) *	1992-12-22	2001-03-13	Sienna Biotech, Inc.	Light scatter-based immunoassay
CA2244326C (fr) *	1997-08-11	2006-03-28	Shinichi Eda	Essai d'agglutination par diffusion de la lumiere, ameliore par des microparticules; reactifs microparticulaires utiles a cette fin
EP0898169B1 (fr)	1997-08-11	2002-02-06	F. Hoffmann-La Roche Ag	Essai à base de la diffusion de la lumière augmenté par les microparticules et réactifs microparticulaires pour la mise en oeuvre de cet essai
EP1147126A4 (fr) *	1998-12-11	2003-07-09	Salk Inst For Biological Studi	Cofacteurs pour facteurs trophiques et procedes d'utilisation
JP2000193662A (ja) *	1998-12-25	2000-07-14	Tomakomai Rinsho Kensa Center:Kk	尿中シスタチンｃ測定試薬及び診断方法並びにキット
KR20010085485A (ko) *	2000-02-29	2001-09-07	추후제출	Ｃ-반응성 단백질 측정방법 및 측정시약
JP4488460B2 (ja) *	2000-08-28	2010-06-23	シスメックス株式会社	免疫分析方法および試薬
JP3398372B1 (ja) *	2001-10-02	2003-04-21	株式会社いかがく	腎疾患の診断用キット
JP2005283250A (ja) *	2004-03-29	2005-10-13	Alfresa Pharma Corp	金コロイド凝集反応の測定方法
CN101680890B (zh) *	2007-05-21	2014-05-07	根田股份有限公司	用于评估人抑半胱氨酸蛋白酶蛋白c的比浊免疫测定

2006
- 2006-11-24 EP EP06849520A patent/EP1952154B1/fr not_active Revoked
- 2006-11-24 US US12/091,952 patent/US8263416B2/en active Active
- 2006-11-24 DE DE602006014581T patent/DE602006014581D1/de active Active
- 2006-11-24 CA CA2627662A patent/CA2627662C/fr active Active
- 2006-11-24 WO PCT/IB2006/004182 patent/WO2007102054A2/fr not_active Ceased
- 2006-11-24 PT PT06849520T patent/PT1952154E/pt unknown
- 2006-11-24 AT AT06849520T patent/ATE469351T1/de active
- 2006-11-24 PL PL06849520T patent/PL1952154T3/pl unknown
- 2006-11-24 ES ES06849520T patent/ES2346572T3/es active Active
- 2006-11-24 JP JP2008541849A patent/JP5147709B2/ja not_active Expired - Fee Related
- 2006-11-24 DK DK06849520.9T patent/DK1952154T3/da active
2012
- 2012-09-05 JP JP2012195362A patent/JP2013007757A/ja active Pending

Also Published As

Publication number	Publication date
PL1952154T3 (pl)	2010-10-29
CA2627662A1 (fr)	2007-09-13
EP1952154B1 (fr)	2010-05-26
WO2007102054A2 (fr)	2007-09-13
DE602006014581D1 (de)	2010-07-08
PT1952154E (pt)	2010-08-27
CA2627662C (fr)	2014-05-13
EP1952154A2 (fr)	2008-08-06
JP2013007757A (ja)	2013-01-10
ATE469351T1 (de)	2010-06-15
US20100047922A1 (en)	2010-02-25
JP2009517649A (ja)	2009-04-30
DK1952154T3 (da)	2010-09-13
WO2007102054A3 (fr)	2008-01-17
US8263416B2 (en)	2012-09-11
JP5147709B2 (ja)	2013-02-20

Publication	Publication Date	Title
US8158443B2 (en)	2012-04-17	Turbidimetric immunoassay for assessing human Cystatin C
JP2013007757A (ja)	2013-01-10	ヒトシスタチンｃを評価するための比濁イムノアッセイ
US9244063B2 (en)	2016-01-26	Immunoassay for assessing related analytes of different origin
AU2016203292B2 (en)	2018-06-07	Monoclonal antibody, and immunoassay using same
ES2297250T3 (es)	2008-05-01	Metodo de ensayo para la deteccion potencial del desarrollo de una enfermedad cardiovascular.
CN110383068A (zh)	2019-10-25	评估患者样品中uch-l1状态的改进方法
WO2010058860A1 (fr)	2010-05-27	Procédé de mesure et réactif de mesure pour la protéine c-réactive dans un échantillon
US7241578B2 (en)	2007-07-10	Immunoassay method/equipment, biological component measurable toilet, anti-albumin monoclonal antibody, cell strain producing the same, and albumin detection kit
CN101356438B (zh)	2013-04-03	评估人半胱氨酸蛋白酶抑制剂c的浊度测定法免疫测定
JP4488460B2 (ja)	2010-06-23	免疫分析方法および試薬
JP2004026805A (ja)	2004-01-29	酒石酸抵抗性酸性ホスファターゼ５ｂに特異的なモノクローナル抗体およびその用途
JP6829689B2 (ja)	2021-02-10	免疫試験方法および免疫試験キット
JPS62238461A (ja)	1987-10-19	補体の定量方法
JP2011117922A (ja)	2011-06-16	アレルギー疾患の検査方法
JP2004061345A (ja)	2004-02-26	尿中のプラスミノーゲンアクチベーターインヒビター−１測定による糖尿病性腎症の進展度の判定方法